Latest updates for Optscureal Limited
Fresh curated links around Optscureal Limited are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Form 8K OSR Holdings Inc For: 3 April
- Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
- Terold Invest Expands UK Platform with Acquisition of Off‑Piste Wines
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
fool.com
/4 days ago
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
wineindustryadvisor.com
/3 weeks ago
Terold Invest Expands UK Platform with Acquisition of Off‑Piste Wines
jvir.org
/4 weeks ago
Abstract No. LBA8 OCCLUDE Final Results: A Prospective, Multicenter, Real-World Study Evaluating the Effectiveness and S...
The OCCLUDE study evaluated the effectiveness and safety of Obsidio Conformable Embolic (Obsidio) for vascular embolization.
newswire.com
/3 days ago
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level
investmentweek.co.uk
/1 month ago
Oberon Investments agrees to FCA restrictions on wealth management arm
Oberon Investments has agreed to Financial Conduct Authority (FCA) restrictions on its wealth management arm, it revealed in a trading update today (14 April).
amrc.org.uk
/1 month ago
Orchard OCD
https://www.orchardocd.org Primary research areas Mental health Grant types Clinical Trials, Project (typically <4 years) and Programme (typically >4 years)
newswire.com
/3 weeks ago
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
biopharmadive.com
/1 month ago
Obsidian, Galera to advance cell therapy following reverse merger
The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement expected to deliver $350 million in gross proceeds.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Optscureal Limited
wineindustryadvisor.com
Recent coverage from public sources
Public source
amrc.org.uk
Recent coverage from public sources
Public source
biopharmadive.com
Recent coverage from public sources
Public source
fool.com
Recent coverage from public sources
Public source
investing.com
Recent coverage from public sources
Public source
investmentweek.co.uk
Recent coverage from public sources
Public source